Overview and Basis of Presentation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended
	Feb. 02, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from common stock offering		$ 38,885	$ 45,255
Common stock, shares issued		76,000,745		74,485,883
Common stock, par value		$ 0.0001		$ 0.0001
Rewrite Therapeutics Delaware Corporation Member
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Upfront consideration payable in cash	$ 45,000
Milestone payments	155,000
Cash	$ 130,000
Common stock, shares issued	25,000,000.0
Common stock, par value	$ 0.0001
IPO [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from common stock offering		$ 1,861,100